Protagonist Therapeutics (PTGX) Misses Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts PTGX Hot Sheet
Join SI Premium – FREE
Protagonist Therapeutics (NASDAQ: PTGX) reported Q2 EPS of ($0.68), $0.03 worse than the analyst estimate of ($0.65).
For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Goldman Sachs Upgrades Protagonist Therapeutics (PTGX) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
